Head to head
Semaglutide against Tesofensine
Appetite suppression through gut hormone signalling against appetite suppression through brain monoamines. The second mechanism is the older one and the one that produced most of the withdrawn weight loss drugs, which is the context worth carrying into any comparison of effect sizes.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
TesofensineTesofensine (triple monoamine reuptake inhibitor)
An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.
Side by side, on the facts we can check
| Attribute | Semaglutide | Tesofensine |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Investigational, not FDA-approved |
| Half-life | ~7 days | ~8 days |
| Molecular weight | 4,113.6 Da | 381.9 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Blocks reuptake of noradrenaline, dopamine, and serotonin, increasing satiety signaling and reducing food intake. |
| Human studies cited | 5 | 2 |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Semaglutide and Tesofensine?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Tesofensine: An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.
Which has stronger research evidence, Semaglutide or Tesofensine?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 2 of 2 for Tesofensine. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Tesofensine FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Tesofensine: Investigational, not FDA-approved.
Related posts
Blog articles that cover Semaglutide or Tesofensine, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.